Access Dermatology

Breaking News

• Home »
• Breaking News »
• Breaking News article

Low-dose methotrexate for moderate-severe adult atopic dermatitis

A retrospective study assessed the efficacy and safety of oral or intramuscular methotrexate, 10-25 mg/week for 8-12 weeks in 20 adult patients with moderate-severe atopic dermatitis (AD) unresponsive to previous treatments. Patients also received 5 mg folic acid/week. Response was assessed by the SCORing Atopic Dermatis index (SCORAD), Dermatology Life Quality Index (DLQI) and a global assessment of the SCORAD and DLQI. There were 16 responders and four nonresponders. Both mean SCORAD and DLQI scores fell significantly after treatment, by 44.3 and 43.5%, respectively. Treatment was more effective in those with adult onset as opposed to childhood onset AD. Methotrexate was well tolerated, although three patients required brief discontinuation of treatment (Lyakhovitsky, ...